Agency Information Collection Activities: Proposed Collection; Comment Request, 13119-13121 [2023-04220]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 41 / Thursday, March 2, 2023 / Notices
identify and describe the role(s) of the
personnel and units authorized to be
involved in incentive compensation
arrangements, identify the source of
significant risk-related inputs, establish
appropriate controls governing these
inputs to help ensure their integrity, and
identify the individual(s) and unit(s)
whose approval is necessary for the
establishment or modification of
incentive compensation arrangements;
(ii) create and maintain sufficient
documentation to permit an audit of the
organization’s processes for incentive
compensation arrangements; (iii) have
any material exceptions or adjustments
to the incentive compensation
arrangements established for senior
executives approved and documented
by its board of directors; and (iv) have
its board of directors receive and
review, on an annual or more frequent
basis, an assessment by management of
the effectiveness of the design and
operation of the organization’s incentive
compensation system in providing risk
taking incentives that are consistent
with the organization’s safety and
soundness. There is no change in the
substance or methodology of this
information collection. The change in
burden is due to a decrease in the
estimated number of respondents. The
burden hours decreased by 358 from
4,368 to 4,010.
Request for Comment
ddrumheller on DSK120RN23PROD with NOTICES1
Comments are invited on: (a) Whether
the collections of information are
necessary for the proper performance of
the FDIC’s functions, including whether
the information has practical utility; (b)
the accuracy of the estimates of the
burden of the information collections,
including the validity of the
methodology and assumptions used; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collections of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. All comments will become
a matter of public record.
Federal Deposit Insurance Corporation.
Dated at Washington, DC, on February 27,
2023.
James P. Sheesley,
Assistant Executive Secretary.
[FR Doc. 2023–04257 Filed 3–1–23; 8:45 am]
BILLING CODE 6714–01–P
VerDate Sep<11>2014
18:21 Mar 01, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
information collection project ‘‘The
AHRQ Safety Program for Telemedicine:
Improving the Diagnostic Process and
Improving Antibiotic Use.’’ This
proposed information collection was
previously published in the Federal
Register on December 15th, 2022 and
allowed 60 days for public comment.
AHRQ received no substantive
comments from members of the public.
The purpose of this notice is to allow an
additional 30 days for public comment.
DATES: Comments on this notice must be
received by April 3, 2023.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Copies of the proposed collection
plans, data collection instruments, and
specific details on the estimated burden
can be obtained from the AHRQ Reports
Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
email at doris.lefkowitz@AHRQ.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Proposed Project
The AHRQ Safety Program for
Telemedicine: Improving the Diagnostic
Process and Improving Antibiotic Use
Telemedicine visits have increased
dramatically in response to the COVID–
19 pandemic and resulting changes in
third-party payer reimbursement
policies. Telemedicine visits increased
from 0.3 percent of all ambulatory visits
in 2019 to 23.6 percent by Spring 2020.
Given this rapid growth, the need to
ensure safe and appropriate patient care
in this setting is urgent. Telemedicine
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
13119
has many benefits, such as facilitating
continuity of care; improving access
beyond normal hours; reducing patients’
travel burden; overcoming health care
provider (HCP) shortages; and providing
support for patients managing chronic
health conditions. However, transferring
clinical practices from an in-person to a
virtual environment poses potential
risks. Many HCPs have never received
formal training in using telemedicine
effectively to diagnose and treat patients
virtually. Additionally, inadequate
internet access, which
disproportionately impacts rural and
minority populations, and struggles
accessing telemedicine platforms may
force video-based telemedicine visits to
transition to audio-only or be skipped.
This program aims to improve two atrisk areas among telemedicine practices
by implementing the AHRQ- and Johns
Hopkins Armstrong Institute for Patient
Safety and Quality (JHAI)-developed
Comprehensive Unit-based Safety
Program (CUSP) approach: (1) the
diagnostic process for breast, colorectal,
and lung cancer; and (2) antibiotic
stewardship (AS). The CUSP approach
improves safety culture at the practice
level, enables harm prevention, and
engages providers who are on the front
lines while integrating technical and
adaptive/cultural approaches to making
sustainable change.
This program constitutes the first
large-scale implementation of a quality
improvement effort for the cancer
diagnostic process and AS in
telemedicine. These areas were chosen
given the need for clearer guidance and
evidence-based telemedicine practices
for clinicians and potential for positive
impact on outcomes. This program will
incorporate CUSP strategies to improve
the diagnostic process for breast,
colorectal, and lung cancer and to
improve antibiotic prescribing in
telemedicine. The program goals are to:
• Identify best practices in
implementing interventions to improve
the cancer diagnostic process and AS in
telemedicine.
• Determine how best to adapt CUSP
to enhance the cancer diagnostic
process and AS in telemedicine.
This study is being conducted by
AHRQ through its contractor,
contractor, NORC at the University of
Chicago (NORC) and NORC’s
subcontractors, the Johns Hopkins
Armstrong Institute of Patient Safety
and Quality (JHAI) and Baylor College
of Medicine (Baylor), pursuant to
AHRQ’s statutory authority to conduct
and support research on health care and
on systems for the delivery of such care,
including activities with respect to the
quality, effectiveness, efficiency,
E:\FR\FM\02MRN1.SGM
02MRN1
13120
Federal Register / Vol. 88, No. 41 / Thursday, March 2, 2023 / Notices
appropriateness and vale of healthcare
services and with respect to quality
measurement and improvement. 42
U.S.C. 299a(a)(1) and (2).
Method of Collection
To achieve the goals of the AHRQ
Safety Program for Telemedicine
(‘‘Safety Program’’), primary and
secondary data collection activities will
include:
(1) Structural Assessment: A brief
online assessment will be completed by
a leader/champion from each practice to
understand practices’ infrastructure and
capacity to implement the Safety
Program.
(2) AHRQ Office Readiness Survey: A
brief online Office Readiness Survey
will be completed by all participating
staff from each practice in the cancer
diagnostic process cohort to understand
practices’ readiness for implementation
of the Safety Program.
(3) The AHRQ Surveys on Patient
Safety Culture: The Medical Office
Survey on Patient Safety Culture
(MOSOPS) (both cohorts) and a
Diagnostic Safety Supplement (cancer
diagnostic process cohort only) will be
completed by all participating staff to
assess patient safety issues, medical
errors, and event reporting practices.
(4) Participant Experience Survey: A
brief online assessment will be
completed by a leader/champion from
each practice to assess how practices
approached implementation of the
Safety Program.
(5) Semi-structured Qualitative
Interviews: A proportion of practices
from both cohorts will be selected to
participate in telephone/virtual
discussions to understand the
facilitators and barriers to implementing
the Safety Program.
(6) Clinical Data Collection Form:
Practices in the cancer diagnostic
process cohort will complete a Clinical
Data Collection Form for patients
suspected of having breast, colorectal, or
lung cancer.
(7) Electronic Health Record (EHR)
Data: Practice-level antibiotic usage and
clinical outcomes data will be extracted
from the EHRs of practices in the AS
cohort.
This data collection effort will be part
of a comprehensive evaluation strategy
to assess the adoption of the Safety
Program among telemedicine practices
comprising the cancer diagnostic
process and AS cohorts; measure the
effectiveness of the Safety Program
among the participating practices and
evaluate how providers experienced the
program as well as the perceived
usefulness of the Safety Program’s
education materials and metrics; and
understand drivers of antibiotic
prescribing among practices in the AS
cohort and drivers of timely follow-up
for patients suspected of having breast,
colorectal, or prostate cancer among
practices in the cancer diagnostic
process cohort.
The evaluation is largely formative in
nature as AHRQ seeks information on
the implementation and effectiveness of
CUSP in a novel setting—telemedicine.
The evaluation will utilize a pre-post
design, comparing data collected at
baseline and at the end of the Safety
Program within each cohort.
Estimated Annual Respondent Burden
Exhibit A.1 shows the estimated
annualized burden hours for the
respondents’ time to complete the
structural assessments, AHRQ office
readiness and patient safety culture
surveys, participant experience surveys,
semi-structured qualitative interviews,
clinical data collection instrument
(collected for 3 patients monthly and
submitted quarterly), and EHR data
extractions (collected monthly and
submitted quarterly). Data will be
collected from up to 300 practices
providing telemedicine for the cancer
diagnostic process cohort and from up
to 500 practices providing telemedicine
for the AS cohort. For the three-year
clearance period, the estimated
annualized burden hours for the data
collection activities are 5,570.
EXHIBIT A.1—ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents *
Form name
1. Structural Assessments (both cohorts) .....................................................
2. AHRQ Office Readiness Survey (cancer diagnostic process cohort only)
3. AHRQ Patient Safety Culture Surveys:
a. MOSOPS (both cohorts) ....................................................................
b. Diagnostic Safety Supplement (cancer diagnostic process cohort
only) ....................................................................................................
4. Participant Experience Survey (both cohorts):
a. Cancer diagnostic process cohort survey ..........................................
b. AS cohort survey ................................................................................
5. Semi-structured qualitative interviews (both cohorts) ...............................
6. Clinical Data Collection Form (cancer diagnostic process cohort) ...........
7. EHR data (AS cohort) ...............................................................................
Total ........................................................................................................
Number of
responses per
respondent
Hours per
response
Total
burden
hours
200
350
2
1
0.2
0.1
80
35
933
2
0.5
933
350
2
0.2
140
75
125
24
90
150
1
1
1
54
18
0.17
0.33
1
0.33
1
13
41
24
1,604
2,700
..........................
........................
........................
5,570
ddrumheller on DSK120RN23PROD with NOTICES1
* Annualized number of respondents is based on maximum practices recruited and 75% response rate for forms 1 and 4a and 4b, 50% response rate for forms 2, 3a and 3b, and 90% response rate for forms 5–7.
Exhibit A.2 shows the estimated
annualized cost burden based on the
respondents’ time to complete the data
collection forms. The total cost burden
is estimated to be $576,922.
EXHIBIT A.2—ESTIMATED ANNUALIZED COST BURDEN
Number of
respondents *
Form name
1. Structural Assessments (both cohorts) .....................................................
VerDate Sep<11>2014
18:21 Mar 01, 2023
Jkt 259001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Total burden
hours
200
E:\FR\FM\02MRN1.SGM
80
02MRN1
Average
hourly wage
rate **
a $111.30
Total
burden
cost
$8,904
13121
Federal Register / Vol. 88, No. 41 / Thursday, March 2, 2023 / Notices
EXHIBIT A.2—ESTIMATED ANNUALIZED COST BURDEN—Continued
Number of
respondents *
Form name
2. AHRQ Office Readiness Survey (cancer diagnostic process cohort only)
3. AHRQ Patient Safety Culture Surveys:
a. MOSOPS (both cohorts):
i. Physicians ....................................................................................
ii. Other Health Practitioners ...........................................................
b. Diagnostic Safety Supplement (cancer diagnostic process cohort
only):
i. Physicians ....................................................................................
ii. Other Health Practitioners ...........................................................
4. Participant Experience Survey (both cohorts) ...........................................
5. Semi-structured qualitative interviews (both cohorts) ...............................
6. Clinical Data Collection Form (cancer diagnostic process cohort only) ...
7. EHR data (AS cohort only) ........................................................................
Total ........................................................................................................
Average
hourly wage
rate **
Total burden
hours
Total
burden
cost
350
35
a 111.30
3,896
466
467
466
467
a 111.30
51,866
14,566
175
175
200
24
90
150
70
70
54
24
1,604
2,700
a 111.30
a 111.30
7,791
2,183
6,010
2,671
178,525
300,510
3,497
5,917
........................
576,922
b 31.19
b 31.19
a 111.30
a 111.30
a 111.30
** Annualized number of respondents is based on maximum practices recruited and 75% response rate for forms 1 and 4, 50% response rate
for forms 2, 3a and 3b, and 90% response rate for forms 5–7.
** National Compensation Survey: Occupational wages in the United States May 2021 ‘‘U.S. Department of Labor, Bureau of Labor Statistics’’:
https://www.bls.gov/oes/current/oes_stru.htm#29-0000.
a Based on the mean wages for 29–1069 Physicians and Surgeons, All Other.
b Based on the mean wages for 29–9099 Miscellaneous Health Practitioners and Technical Workers: Healthcare Practitioners and Technical
Workers, All Other.
Request for Comments
ddrumheller on DSK120RN23PROD with NOTICES1
In accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3520,
comments on AHRQ’s information
collection are requested with regard to
any of the following: (a) whether the
proposed collection of information is
necessary for the proper performance of
AHRQ’s health care research and health
care information dissemination
functions, including whether the
information will have practical utility;
(b) the accuracy of AHRQ’s estimate of
burden (including hours and costs) of
the proposed collection(s) of
information; (c) ways to enhance the
quality, utility and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Dated: February 23, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023–04220 Filed 3–1–23; 8:45 am]
BILLING CODE 4160–90–P
VerDate Sep<11>2014
18:21 Mar 01, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)–
GH23–003, Conducting Public Health
Research with Universities in Thailand.
Date: April 12, 2023.
Time: 9 a.m.–2:30 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Hylan Shoob, Ph.D., Scientific Review
Officer, Center for Global Health, CDC,
1600 Clifton Road NE, Mailstop H21–9,
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Atlanta, Georgia 30329–4027;
Telephone: (404) 639–4796; Email:
HShoob@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–04241 Filed 3–1–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
E:\FR\FM\02MRN1.SGM
02MRN1
]]>Agencies
[Federal Register Volume 88, Number 41 (Thursday, March 2, 2023)]
[Notices]
[Pages 13119-13121]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-04220]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Agency for Healthcare Research and Quality, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the intention of the Agency for
Healthcare Research and Quality (AHRQ) to request that the Office of
Management and Budget (OMB) approve the proposed information collection
project ``The AHRQ Safety Program for Telemedicine: Improving the
Diagnostic Process and Improving Antibiotic Use.'' This proposed
information collection was previously published in the Federal Register
on December 15th, 2022 and allowed 60 days for public comment. AHRQ
received no substantive comments from members of the public. The
purpose of this notice is to allow an additional 30 days for public
comment.
DATES: Comments on this notice must be received by April 3, 2023.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.
Copies of the proposed collection plans, data collection
instruments, and specific details on the estimated burden can be
obtained from the AHRQ Reports Clearance Officer.
FOR FURTHER INFORMATION CONTACT: Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427-1477, or by email at
[email protected].
SUPPLEMENTARY INFORMATION:
Proposed Project
The AHRQ Safety Program for Telemedicine: Improving the Diagnostic
Process and Improving Antibiotic Use
Telemedicine visits have increased dramatically in response to the
COVID-19 pandemic and resulting changes in third-party payer
reimbursement policies. Telemedicine visits increased from 0.3 percent
of all ambulatory visits in 2019 to 23.6 percent by Spring 2020. Given
this rapid growth, the need to ensure safe and appropriate patient care
in this setting is urgent. Telemedicine has many benefits, such as
facilitating continuity of care; improving access beyond normal hours;
reducing patients' travel burden; overcoming health care provider (HCP)
shortages; and providing support for patients managing chronic health
conditions. However, transferring clinical practices from an in-person
to a virtual environment poses potential risks. Many HCPs have never
received formal training in using telemedicine effectively to diagnose
and treat patients virtually. Additionally, inadequate internet access,
which disproportionately impacts rural and minority populations, and
struggles accessing telemedicine platforms may force video-based
telemedicine visits to transition to audio-only or be skipped.
This program aims to improve two at-risk areas among telemedicine
practices by implementing the AHRQ- and Johns Hopkins Armstrong
Institute for Patient Safety and Quality (JHAI)-developed Comprehensive
Unit-based Safety Program (CUSP) approach: (1) the diagnostic process
for breast, colorectal, and lung cancer; and (2) antibiotic stewardship
(AS). The CUSP approach improves safety culture at the practice level,
enables harm prevention, and engages providers who are on the front
lines while integrating technical and adaptive/cultural approaches to
making sustainable change.
This program constitutes the first large-scale implementation of a
quality improvement effort for the cancer diagnostic process and AS in
telemedicine. These areas were chosen given the need for clearer
guidance and evidence-based telemedicine practices for clinicians and
potential for positive impact on outcomes. This program will
incorporate CUSP strategies to improve the diagnostic process for
breast, colorectal, and lung cancer and to improve antibiotic
prescribing in telemedicine. The program goals are to:
Identify best practices in implementing interventions to
improve the cancer diagnostic process and AS in telemedicine.
Determine how best to adapt CUSP to enhance the cancer
diagnostic process and AS in telemedicine.
This study is being conducted by AHRQ through its contractor,
contractor, NORC at the University of Chicago (NORC) and NORC's
subcontractors, the Johns Hopkins Armstrong Institute of Patient Safety
and Quality (JHAI) and Baylor College of Medicine (Baylor), pursuant to
AHRQ's statutory authority to conduct and support research on health
care and on systems for the delivery of such care, including activities
with respect to the quality, effectiveness, efficiency,
[[Page 13120]]
appropriateness and vale of healthcare services and with respect to
quality measurement and improvement. 42 U.S.C. 299a(a)(1) and (2).
Method of Collection
To achieve the goals of the AHRQ Safety Program for Telemedicine
(``Safety Program''), primary and secondary data collection activities
will include:
(1) Structural Assessment: A brief online assessment will be
completed by a leader/champion from each practice to understand
practices' infrastructure and capacity to implement the Safety Program.
(2) AHRQ Office Readiness Survey: A brief online Office Readiness
Survey will be completed by all participating staff from each practice
in the cancer diagnostic process cohort to understand practices'
readiness for implementation of the Safety Program.
(3) The AHRQ Surveys on Patient Safety Culture: The Medical Office
Survey on Patient Safety Culture (MOSOPS) (both cohorts) and a
Diagnostic Safety Supplement (cancer diagnostic process cohort only)
will be completed by all participating staff to assess patient safety
issues, medical errors, and event reporting practices.
(4) Participant Experience Survey: A brief online assessment will
be completed by a leader/champion from each practice to assess how
practices approached implementation of the Safety Program.
(5) Semi-structured Qualitative Interviews: A proportion of
practices from both cohorts will be selected to participate in
telephone/virtual discussions to understand the facilitators and
barriers to implementing the Safety Program.
(6) Clinical Data Collection Form: Practices in the cancer
diagnostic process cohort will complete a Clinical Data Collection Form
for patients suspected of having breast, colorectal, or lung cancer.
(7) Electronic Health Record (EHR) Data: Practice-level antibiotic
usage and clinical outcomes data will be extracted from the EHRs of
practices in the AS cohort.
This data collection effort will be part of a comprehensive
evaluation strategy to assess the adoption of the Safety Program among
telemedicine practices comprising the cancer diagnostic process and AS
cohorts; measure the effectiveness of the Safety Program among the
participating practices and evaluate how providers experienced the
program as well as the perceived usefulness of the Safety Program's
education materials and metrics; and understand drivers of antibiotic
prescribing among practices in the AS cohort and drivers of timely
follow-up for patients suspected of having breast, colorectal, or
prostate cancer among practices in the cancer diagnostic process
cohort.
The evaluation is largely formative in nature as AHRQ seeks
information on the implementation and effectiveness of CUSP in a novel
setting--telemedicine. The evaluation will utilize a pre-post design,
comparing data collected at baseline and at the end of the Safety
Program within each cohort.
Estimated Annual Respondent Burden
Exhibit A.1 shows the estimated annualized burden hours for the
respondents' time to complete the structural assessments, AHRQ office
readiness and patient safety culture surveys, participant experience
surveys, semi-structured qualitative interviews, clinical data
collection instrument (collected for 3 patients monthly and submitted
quarterly), and EHR data extractions (collected monthly and submitted
quarterly). Data will be collected from up to 300 practices providing
telemedicine for the cancer diagnostic process cohort and from up to
500 practices providing telemedicine for the AS cohort. For the three-
year clearance period, the estimated annualized burden hours for the
data collection activities are 5,570.
Exhibit A.1--Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of
Form name Number of responses per Hours per Total burden
respondents * respondent response hours
----------------------------------------------------------------------------------------------------------------
1. Structural Assessments (both cohorts)....... 200 2 0.2 80
2. AHRQ Office Readiness Survey (cancer 350 1 0.1 35
diagnostic process cohort only)...............
3. AHRQ Patient Safety Culture Surveys:
a. MOSOPS (both cohorts)................... 933 2 0.5 933
b. Diagnostic Safety Supplement (cancer 350 2 0.2 140
diagnostic process cohort only)...........
4. Participant Experience Survey (both
cohorts):
a. Cancer diagnostic process cohort survey. 75 1 0.17 13
b. AS cohort survey........................ 125 1 0.33 41
5. Semi-structured qualitative interviews (both 24 1 1 24
cohorts)......................................
6. Clinical Data Collection Form (cancer 90 54 0.33 1,604
diagnostic process cohort)....................
7. EHR data (AS cohort)........................ 150 18 1 2,700
----------------------------------------------------------------
Total...................................... ............... .............. .............. 5,570
----------------------------------------------------------------------------------------------------------------
* Annualized number of respondents is based on maximum practices recruited and 75% response rate for forms 1 and
4a and 4b, 50% response rate for forms 2, 3a and 3b, and 90% response rate for forms 5-7.
Exhibit A.2 shows the estimated annualized cost burden based on the
respondents' time to complete the data collection forms. The total cost
burden is estimated to be $576,922.
Exhibit A.2--Estimated Annualized Cost Burden
----------------------------------------------------------------------------------------------------------------
Average
Form name Number of Total burden hourly wage Total burden
respondents * hours rate ** cost
----------------------------------------------------------------------------------------------------------------
1. Structural Assessments (both cohorts)....... 200 80 a $111.30 $8,904
[[Page 13121]]
2. AHRQ Office Readiness Survey (cancer 350 35 a 111.30 3,896
diagnostic process cohort only)...............
3. AHRQ Patient Safety Culture Surveys:
a. MOSOPS (both cohorts):
i. Physicians.......................... 466 466 a 111.30 51,866
ii. Other Health Practitioners......... 467 467 b 31.19 14,566
b. Diagnostic Safety Supplement (cancer
diagnostic process cohort only):
i. Physicians.......................... 175 70 a 111.30 7,791
ii. Other Health Practitioners......... 175 70 b 31.19 2,183
4. Participant Experience Survey (both cohorts) 200 54 a 111.30 6,010
5. Semi-structured qualitative interviews (both 24 24 a 111.30 2,671
cohorts)......................................
6. Clinical Data Collection Form (cancer 90 1,604 a 111.30 178,525
diagnostic process cohort only)...............
7. EHR data (AS cohort only)................... 150 2,700 a 111.30 300,510
----------------------------------------------------------------
Total...................................... 3,497 5,917 .............. 576,922
----------------------------------------------------------------------------------------------------------------
** Annualized number of respondents is based on maximum practices recruited and 75% response rate for forms 1
and 4, 50% response rate for forms 2, 3a and 3b, and 90% response rate for forms 5-7.
** National Compensation Survey: Occupational wages in the United States May 2021 ``U.S. Department of Labor,
Bureau of Labor Statistics'': https://www.bls.gov/oes/current/oes_stru.htm#29-0000.
\a\ Based on the mean wages for 29-1069 Physicians and Surgeons, All Other.
\b\ Based on the mean wages for 29-9099 Miscellaneous Health Practitioners and Technical Workers: Healthcare
Practitioners and Technical Workers, All Other.
Request for Comments
In accordance with the Paperwork Reduction Act, 44 U.S.C. 3501-
3520, comments on AHRQ's information collection are requested with
regard to any of the following: (a) whether the proposed collection of
information is necessary for the proper performance of AHRQ's health
care research and health care information dissemination functions,
including whether the information will have practical utility; (b) the
accuracy of AHRQ's estimate of burden (including hours and costs) of
the proposed collection(s) of information; (c) ways to enhance the
quality, utility and clarity of the information to be collected; and
(d) ways to minimize the burden of the collection of information upon
the respondents, including the use of automated collection techniques
or other forms of information technology.
Comments submitted in response to this notice will be summarized
and included in the Agency's subsequent request for OMB approval of the
proposed information collection. All comments will become a matter of
public record.
Dated: February 23, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023-04220 Filed 3-1-23; 8:45 am]
BILLING CODE 4160-90-P
